Literature DB >> 32176759

Association of Serum Homocysteine Levels with Histological Severity of NAFLD.

Yilun Xu1, Yaqi Guan2, Xingyi Yang3, Ziqiang Xia4, Jinming Wu5.   

Abstract

BACKGROUND AND AIMS: Studies on the association between homocysteine and non-alcoholic fatty liver disease (NAFLD) have shown inconsistent results. Our study concerns the association of homocysteine with the histological severity of NAFLD, especially non-alcoholic steatohepatitis (NASH) and significant fibrosis (SF) after adjusting for other well-identified risk factors.
METHODS: This study enrolled 289 patients with biopsy proven NAFLD. The association of homocysteine with the severe histological features was examined using multivariable logistic regression analysis and subgroup analysis. The area under curves (AUC) and Hosmer-Lemeshow goodness-of-fit test for the adjusted logistic regression models was analyzed.
RESULTS: After multivariable regression analysis, homocysteine showed significant correlation with NASH (OR 0.79 95%CI: 0.69-0.89), p<0.001) and SF (OR 0.83 95%CI: 0.72-0.95, p=0.009). Spearman's correlation analysis showed homocysteine levels were inversely correlated with the grade of hepatocellular ballooning and the stage of liver fibrosis (Spearman's ρ=-0.13, p=0.033; Spearman's ρ=-0.16, p=0.007), but had no correlation with the severity of steatosis and lobular inflammation. The subgroup analyses showed that homocysteine was strongly associated with NASH in females but was weaker in males (female OR: 0.61 95%CI: 0.45-0.84; male 0.86 95%CI: 0.75-0.99), and on SF showed no significant differences in the subgroups. The models showed good discrimination for NASH (AUC 0.789, 95% CI: 0.736-0.843) and for SF (0.784 95%CI: 0.719-0.848) and calibration (Hosmer-Lemeshow goodness-of-fit test, p=0.346 for NASH; p=0.908 for SF).
CONCLUSION: Elevated serum homocysteine levels are negatively associated with NASH and SF in subjects with NAFLD.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32176759     DOI: 10.15403/jgld-529

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  8 in total

Review 1.  Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication.

Authors:  Zhanghao Li; Feixia Wang; Baoyu Liang; Ying Su; Sumin Sun; Siwei Xia; Jiangjuan Shao; Zili Zhang; Min Hong; Feng Zhang; Shizhong Zheng
Journal:  Signal Transduct Target Ther       Date:  2020-12-04

2.  Gender differences in risk factors for high plasma homocysteine levels based on a retrospective checkup cohort using a generalized estimating equation analysis.

Authors:  Jing Zhao; Zhihua Li; Chengbei Hou; Fei Sun; Jing Dong; Xi Chu; Yansu Guo
Journal:  Lipids Health Dis       Date:  2021-04-12       Impact factor: 3.876

3.  Association of serum methionine metabolites with non-alcoholic fatty liver disease: a cross-sectional study.

Authors:  Yi Tang; Xu Chen; Qian Chen; Jinghe Xiao; Jiaxin Mi; Qiannan Liu; Yiran You; Yuming Chen; Wenhua Ling
Journal:  Nutr Metab (Lond)       Date:  2022-03-18       Impact factor: 4.169

4.  The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.

Authors:  Hamid Reza Talari; Mohamad Reza Molaqanbari; Milad Mokfi; Mohsen Taghizadeh; Fereshteh Bahmani; Seyed Mohammad Hossein Tabatabaei; Nasrin Sharifi
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

Review 5.  NAFLD and cardiovascular diseases: a clinical review.

Authors:  Philipp Kasper; Anna Martin; Sonja Lang; Fabian Kütting; Tobias Goeser; Münevver Demir; Hans-Michael Steffen
Journal:  Clin Res Cardiol       Date:  2020-07-21       Impact factor: 5.460

Review 6.  Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications.

Authors:  Shiyao Zhang; Mengyi Xu; Wenxiang Zhang; Chang Liu; Siyu Chen
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

Review 7.  The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease.

Authors:  Mikkel Parsberg Werge; Adrian McCann; Elisabeth Douglas Galsgaard; Dorte Holst; Anne Bugge; Nicolai J Wewer Albrechtsen; Lise Lotte Gluud
Journal:  J Clin Med       Date:  2021-03-05       Impact factor: 4.241

8.  The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004.

Authors:  Li Li; Qi Huang; Linjian Yang; Rui Zhang; Leili Gao; Xueyao Han; Linong Ji; Xiantong Zou
Journal:  Nutrients       Date:  2022-03-14       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.